Anti-Human IL5 Recombinant Antibody (Mepolizumab) (CAT#: TAB-031)

Figure 1 Anti-interleukin (IL)-5 (mepolizumab) decreases β2 but not β1 integrin activation on blood eosinophils.

Reactivity of monoclonal antibody (A) KIM-127 (to the intermediate-activity state of β2 integrin), and (b) N29 (to the intermediate-activity state of β1 integrin) on blood eosinophils before (green) and after (blue) anti-IL-5 mepolizumab administration. Red, isotype control. A representative subject with mild allergic asthma from Ref. (34).

Johansson, M. W. . (2017). Eosinophil activation status in separate compartments and association with asthma. Frontiers in Medicine, 4, 75-.

Figure 2 Photomicrographs of esophageal biopsies before and after anti–IL-5 therapy. Biopsies from the distalesophagus before (A, B) and after (C, D) anti–IL-5 therapy (mepolizumab).

The photomicrographs have been selected to demonstrate representative well oriented (A, C) and typical biopsies with maximal tissue pathology (B, D). Note the presence of marked eosinophilic inflammation and epithelial hyperplasia before (week 8) and reduced eosinophilic inflammation and epithelial hyperplasia after (week 20) anti–IL-5. The photomicrographs were taken from patient number 4. Original magnification, 3400.

Osterman, & M. (2007). Anti-il-5 (mepolizumab) therapy for eosinophilic esophagitis. Yearbook of Gastroenterology, 2007, 169.

Figure 1 Anti-Human IL5 Recombinant Antibody (TAB-031) in SDS-PAGE

Lane 1: Human IgG1, κ Isotype control (5.0 μg) (Reduced)
Lane 2: TAB-031 (5.0 μg) (Reduced)
Lane 3: Human IgG1, κ Isotype control (5.0 μg) (Non-reduced)
Lane 4: TAB-031 (5.0 μg) (Non-reduced)
M: SDS-PAGE Marker